Dendritic cell-based cancer immunotherapy for colorectal cancer

doi:10.3748/wjg.v22.i17.4275

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9572)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

861

WORD

358

HTML

5602

Tables (1-2)

272

Sum=7093

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1020

Download

1459

Sum=2479

May 7, 2016 (publication date) through Jan 9, 2025

Times Cited of This Article

Times Cited (32)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. May 7, 2016; 22(17): 4275-4286
Published online May 7, 2016. doi: 10.3748/wjg.v22.i17.4275

Table 2 Clinical trials of immune checkpoint therapy in patients with colorectal cancer

Target	Immunotherapy	Phase	Patients	Results	Ref	Year
PD-1	Pembrolizumab, anti-PD-1 immune checkpoint inhibitor	II	11 MMR-deficient CRC, 21 MMR-proficient CRC, and 9 MMR-deficient non-CRC	The immune-related objective response rate and immune-related progression-free survival rate were 40% (4 of 10 patients) and 78% (7 of 9 patients), respectively, for MMR-deficient CRC and 0% (0 of 18 patients) and 11% (2 of 18 patients) for MMR-proficient CRC	Le et al[89]	2015

PD-1: Programmed death 1; CRC: Colorectal cancer; MMR: DNA mismatch repair.

Citation: Kajihara M, Takakura K, Kanai T, Ito Z, Saito K, Takami S, Shimodaira S, Okamoto M, Ohkusa T, Koido S. Dendritic cell-based cancer immunotherapy for colorectal cancer. World J Gastroenterol 2016; 22(17): 4275-4286
URL: https://www.wjgnet.com/1007-9327/full/v22/i17/4275.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i17.4275